Restructuring Activities

6 Months Ended

Jun. 30, 2011

NOTE D – Restructuring Activities

In April 2010, Caire Inc., a wholly-owned subsidiary of the Company, announced its plan to close its liquid oxygen therapy manufacturing facility in Plainfield, Indiana and relocate the manufacturing and customer service operations to a facility close to existing BioMedical operations in Canton, Georgia. The Plainfield facility was acquired as part of the 2009 acquisition of the liquid oxygen therapy business of Covidien plc. The closure was substantially completed in the second quarter of 2011. The total anticipated cost of the restructuring is approximately $7,000 which includes asset impairment charges. The cost includes cash expenditures for employee retention and separation benefits, as well as lease exit costs and loss on disposal of remaining assetes. For the three and six months ended June 30, 2011, the Company recorded $2,280 and $2,479, respectively, related to the closure of the Plainfield, Indiana BioMedical facility and also recorded $78 and $981, respectively, in restructuring costs for employee separation benefits related to the integration of SeQual Technologies Inc., which was acquired on December 28, 2010. These charges were recorded in cost of sales ($953 and $965 for the three and six months ended June 30, 2011, respectively), selling, general and administrative expenses ($652 and $1,742 for the three and six months ended June 30, 2011, respectively), and loss on disposal of assets ($1,216 for the three and six months ended June 30, 2011, respectively).

The following tables summarize the Company's restructuring activities for the three and six months ended June 30, 2011 and the three and six months ended June 30, 2010.


	Three Months Ended June 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance at March 31, 2011	$	64		$	259		$	2,400		$	—		$	2,723
Restructuring charges		—			27			2,358			437			2,822
Loss on disposal of assets		—			—			(1,216	)		—			(1,216	)
Cash payments		(64	)		(129	)		(1,576	)		(437	)		(2,206	)

Balance as of June 30, 2011	$	—		$	157		$	1,966		$	—		$	2,123


	Six Months Ended June 30, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance at January 1, 2011	$	103		$	388		$	2,088		$	—		$	2,579
Restructuring charges		—			26			3,460			437			3,923
Loss on dispoal of assets		—			—			(1,216	)		—			(1,216	)
Cash payments		(103	)		(257	)		(2,366	)		(437	)		(3,163	)

Balance as of June 30, 2011	$	—		$	157		$	1,966		$	—		$	2,123


	Three Months Ended June 30, 2010
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance at March 31, 2010	$	305		$	1,182		$	220		$	22		$	1,729
Restructuring charges		—			(41	)		1,960			(22	)		1,897
Asset impairment		—			—			(700	)		—			(700	)
Cash payments		(49	)		(339	)		(430	)		—			(818	)

Balance as of June 30, 2010	$	256		$	802		$	1,050		$	—		$	2,108


	Six Months Ended June 30, 2010
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance at January 1, 2010	$	682		$	1,608		$	503		$	88		$	2,881
Restructuring charges		—			(41	)		1,995			(22	)		1,932
Asset impairment		—			—			(700	)		—			(700	)
Cash payments		(426	)		(765	)		(748	)		(66	)		(2,005	)

Balance as of June 30, 2010	$	256		$	802		$	1,050		$	—		$	2,108

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details